Genic제닉
123330 · KOSDAQ · ₩123330 · 제닉
₩15,470▼ ₩400 (2.52%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩78B | ₩50B | ₩28B | ₩31B | ₩38B |
| Cost of sales | ₩56B | ₩38B | ₩25B | ₩29B | ₩31B |
| Gross profit | ₩23B | ₩12B | ₩3.2B | ₩2.7B | ₩6.9B |
| Operating income | ₩15B | ₩6B | −₩4B | −₩3.2B | −₩3.9B |
| Net income | ₩19B | ₩7.6B | −₩4.4B | −₩3.3B | −₩4.3B |
| Net income to shareholders | ₩19B | ₩7.6B | −₩4.4B | −₩3.3B | −₩4.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩57B | ₩38B | ₩23B | ₩30B | ₩45B |
| Current assets | ₩31B | ₩21B | ₩9.4B | ₩15B | ₩30B |
| Cash and equivalents | ₩13B | ₩1.3B | ₩1.7B | ₩3.4B | ₩17B |
| Total liabilities | ₩15B | ₩16B | ₩12B | ₩14B | ₩26B |
| Current liabilities | ₩13B | ₩15B | ₩12B | ₩14B | ₩16B |
| Borrowings | ₩2.2B | ₩5B | ₩7B | ₩11B | ₩20B |
| Total equity | ₩41B | ₩22B | ₩12B | ₩16B | ₩19B |
| Shareholders' equity | ₩41B | ₩22B | ₩12B | ₩16B | ₩19B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩21B | ₩272M | −₩268M | ₩186M | ₩2.6B |
| Capital spending | ₩2.7B | ₩1.7B | ₩841M | ₩1.4B | ₩649M |
| Free cash flow | ₩18B | −₩1.4B | −₩1.1B | −₩1.2B | ₩1.9B |
Consolidated where available. Amounts in won.
Also known as: Genic / 제닉 / 123330 / KRX:123330
Source: KRX statistical information